This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caudell, D. Articles by Aplan, P. D. Search for Related Content PubMed PubMed Citation Articles by Caudell, D. Articles by Aplan, P. D.

Expression of a CALM-AF10 Fusion Gene Leads to Hoxa Cluster Overexpression and Acute Leukemia in Transgenic Mice

¹ Genetics Branch and ² Comparative Molecular Pathology Unit, National Cancer Institute, National Institutes for Health, Bethesda, Maryland and ³ Department of Veterinary Medical Sciences, University of Maryland, College Park, Maryland

Requests for reprints: Peter D. Aplan, Navy 8, Room 5101, 8901 Wisconsin Avenue, Bethesda, MD 20889. Phone: 301-435-5005; Fax: 301-496-0047; E-mail: aplanp{at}mail.nih.gov.

To assess the role of the CALM-AF10 fusion gene in leukemic transformation in vivo, we generated transgenic mice that expressed a CALM-AF10 fusion gene. Depending on the transgenic line, at least 40% to 50% of the F₁ generation mice developed acute leukemia at a median age of 12 months. Leukemic mice typically had enlarged spleens, invasion of parenchymal organs with malignant cells, and tumors with myeloid markers such as myeloperoxidase, Mac1, and Gr1. Although most leukemias were acute myeloid leukemia, many showed lymphoid features, such as CD3 staining, or clonal Tcrb or Igh gene rearrangements. Mice were clinically healthy for the first 9 months of life and had normal peripheral blood hemograms but showed impaired thymocyte differentiation, manifested by decreased CD4⁺/CD8⁺ cells and increased immature CD4^–/CD8^– cells in the thymus. Hematopoietic tissues from both clinically healthy and leukemic CALM-AF10 mice showed up-regulation of Hoxa cluster genes, suggesting a potential mechanism for the impaired differentiation. The long latency period and incomplete penetrance suggest that additional genetic events are needed to complement the CALM-AF10 transgene and complete the process of leukemic transformation. [Cancer Res 2007;67(17):8022–31]

This article has been cited by other articles:

				Y.-H. Lin, P. M. Kakadia, Y. Chen, Y.-Q. Li, A. J. Deshpande, C. Buske, K.-L. Zhang, Y. Zhang, G.-L. Xu, and S. K. Bohlander Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias Blood, July 16, 2009; 114(3): 651 - 658. [Abstract] [Full Text] [PDF]

				D. Jankovic, P. Gorello, T. Liu, S. Ehret, R. La Starza, C. Desjobert, F. Baty, M. Brutsche, P.-S. Jayaraman, A. Santoro, et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia Blood, June 15, 2008; 111(12): 5672 - 5682. [Abstract] [Full Text] [PDF]